drugset / Trial / NCT04075604

A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer

NCT04075604

Phase 2 Completed 23 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelTreatment

Summary

A randomized multi-arm study evaluating the safety and efficacy of palbociclib and anastrozole with or without nivolumab in participants with ER+/HER2- breast cancer

Timeline

Start
2019-10-18
Primary completion
2021-07-27
Completion
2021-07-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Anastrozole Other / unclassified
Subject Nivolumab Monoclonal antibody
Subject Palbociclib Small molecule

Indications